Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2015-09-04 Interim / Quarterly Rep…
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Half yearly financial report
Interim / Quarterly Report Classification · 100% confidence The document is titled '2015 HALF YEAR FINANCIAL REPORT' and contains comprehensive condensed consolidated financial statements, including income statements, balance sheets, and cash flow statements for the six-month period ending June 30, 2015. It includes detailed notes and auditor review reports, which confirms it is a substantive interim financial report rather than a mere announcement or summary. H2 2015
2015-09-04 English
Rapport financier semestriel
Interim / Quarterly Report Classification · 100% confidence The document is a 'Rapport Financier Semestriel 2015' (Half-Year Financial Report 2015) for Ipsen S.A. It contains comprehensive financial statements, including the consolidated income statement, statement of comprehensive income, consolidated balance sheet, and cash flow statement for the period ending June 30, 2015. As it provides substantive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H2 2015
2015-09-04 French
Share buybacks / Liquidity contracts Description of share buyback program
Transaction in Own Shares Classification · 99% confidence The document explicitly details 'Disclosure of transactions in own shares' over a specific period (24/08/2015 to 28/08/2015), showing the number of shares purchased and the weighted average price. This directly corresponds to the definition of 'Transaction in Own Shares' (share repurchase/issuance), which maps to the filing code POS.
2015-08-31 English
Rachat d'actions / Contrat de liquidité Descriptif du programme de rachat
Transaction in Own Shares Classification · 100% confidence The document title is "Déclaration des transactions sur actions propres réalisées du 24/08/2015 au 28/08/2015" (Declaration of transactions on own shares carried out from 08/24/2015 to 08/28/2015). The content is a table detailing the purchase ('ACHAT') of 20,000 shares over five days, including quantities, weighted average price, and total amount. This directly corresponds to the definition of 'Transaction in Own Shares' (share repurchase/issuance). Therefore, the correct filing type code is POS.
2015-08-31 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release dated August 31, 2015, announcing the publication of Phase III study results for the drug Dysport® in The Lancet Neurology. It details clinical trial outcomes (efficacy, safety, endpoints like MAS and PGA), mentions regulatory filings (FDA approval in the US, ongoing submissions in EU/RoW), and includes quotes from R&D leadership and an external physician. This content structure—announcing positive clinical/regulatory news via a press release—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is focused on announcing the results of a specific study and subsequent regulatory actions, and not a comprehensive periodic financial report (like 10-K or IR), it fits best as an Earnings Release (ER) if it were tied to a reporting period, or more generally, a Regulatory Filing (RNS) if it's a standalone announcement of scientific/regulatory progress. Given the focus on scientific data publication and regulatory milestones rather than quarterly financial performance highlights, RNS is a strong candidate. However, many companies use ERs to disseminate significant clinical trial data alongside financial updates, or as a standalone announcement of major news. Since the document is a formal announcement of a significant event (publication of Phase III data leading to regulatory action) and is not a full report, and it doesn't fit the specific definitions of other codes (like LTR for legal proceedings or CAP for financing), RNS (Regulatory Filings/General Announcement) is the most appropriate general category for this type of corporate news release that isn't a standard financial report or call transcript.
2015-08-31 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 90% confidence The document is a press release dated August 31, 2015, announcing the publication of Phase III clinical trial results for the drug Dysport® in *The Lancet Neurology*. It details the study methodology, efficacy results, and regulatory submissions (FDA approval in the US, ongoing procedures in Europe). This type of announcement, which communicates significant clinical trial outcomes and regulatory milestones, is typically classified as an Earnings Release (ER) if it were tied to a quarterly report, or more generally as a Regulatory Filing (RNS) if it's a standalone announcement of scientific/regulatory progress. However, given the detailed nature of the scientific results and the focus on clinical data publication, it strongly aligns with an announcement of scientific/clinical progress. Since there is no specific category for 'Clinical Trial Results Announcement' and it is not a full financial report (10-K, IR) or a management discussion (MDA), the most appropriate category among the provided options that covers significant, non-financial regulatory/scientific updates is 'Regulatory Filings' (RNS), as it details regulatory actions (FDA approval) and scientific publication. Alternatively, if the focus is purely on the scientific data release, it could be seen as a general corporate communication. Given the mention of regulatory submissions and approvals, RNS is the best fit as a general regulatory/corporate update.
2015-08-31 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.